[The first experience with the use of divozilimab in the treatment of multiple sclerosis patients in daily clinical practice].
V M LebedevE D KuzminykhPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2024)
The data from post-registration use of divozilimab confirm the results of clinical trials, showing high efficacy of the drug with a predictable and favorable safety profile.
Keyphrases
- multiple sclerosis
- clinical trial
- end stage renal disease
- clinical practice
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- physical activity
- randomized controlled trial
- emergency department
- electronic health record
- big data
- machine learning
- patient reported outcomes
- patient reported
- phase iii